Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.
Freeman CL, Atkins R, Varadarajan I, Menges M, Edelman J, Baz R, Brayer J, Castaneda Puglianini O, Ochoa-Bayona JL, Nishihori T, Shain KH, Shah B, Chen DT, Kelley L, Coppola D, Alsina M, Antonia S, Anasetti C, Locke FL. Freeman CL, et al. Among authors: ochoa bayona jl. Clin Cancer Res. 2023 Nov 14;29(22):4575-4585. doi: 10.1158/1078-0432.CCR-22-3987. Clin Cancer Res. 2023. PMID: 37735756
Sirolimus for treatment of steroid-refractory acute graft-versus-host disease.
Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Hoda D, et al. Bone Marrow Transplant. 2010 Aug;45(8):1347-51. doi: 10.1038/bmt.2009.343. Epub 2009 Dec 7. Bone Marrow Transplant. 2010. PMID: 19966849
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications.
Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Pidala J, et al. Int J Hematol. 2011 Feb;93(2):206-212. doi: 10.1007/s12185-010-0747-x. Epub 2011 Jan 19. Int J Hematol. 2011. PMID: 21246311 Free PMC article.
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.
Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Nishihori T, et al. Br J Haematol. 2012 Jun;157(5):553-63. doi: 10.1111/j.1365-2141.2012.09099.x. Epub 2012 Mar 26. Br J Haematol. 2012. PMID: 22449149 Free PMC article. Clinical Trial.
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.
Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Kharfan-Dabaja MA, et al. Biol Blood Marrow Transplant. 2013 Jul;19(7):1087-93. doi: 10.1016/j.bbmt.2013.04.020. Epub 2013 Apr 28. Biol Blood Marrow Transplant. 2013. PMID: 23632090 Free PMC article. Clinical Trial.
26 results